Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New analyst... Good news
Research analysts at Ascendiant Capital Markets assumed coverage on shares of Apricus Biosciences (NASDAQ: APRI) in a report released on Monday. The firm set a “strong-buy” rating and a $6.00 price target on the stock.
http://www.dailypolitical.com/finance/stock-market/ascendiant-capital-markets-analysts-begin-coverage-on-apricus-biosciences-apri.htm
Fair enough Thurly, I respect your opinion and your fear...
I sense in your post your little Fear, your little Uncertainty and the little Doubt... which of course you are entitled to have
But I just listened again to the Q2 and I dont know where you get that from... I really wish I see the root of your concern cause I dont want to make mistakes with my money...
From the C.C this is the part I think you are refering to: (the person who asked seemed to be happy with the reply)
"... Raluca Pancratov - Roth Capital Partners, LLC, Research Division
This is Luca Pancratov in for Joe. So I was wondering for the Phase II randomized study, can you please give me a breakdown of the U.S. versus x US patients?
Joseph S. Shan
Yes, I think we haven't given a lot of color to that publicly and we're reserving that for a upcoming medical conference. But I think we have said that about half the patients came from the U.S. whereas the remaining coming from international sites.
Raluca Pancratov - Roth Capital Partners, LLC, Research Division
Is there any color you can also provide on powering assumptions for this study at all?
Joseph S. Shan
Again, Phase II study is not necessarily designed for robustness, fiscal powering. However, we do plan on providing that level of detail at a medical conference.
Raluca Pancratov - Roth Capital Partners, LLC, Research Division
Right. I see, I see. So I'm guessing the data is still maturing. And then probably at a medical conference, you could also provide some analysis of subgroups?
Joseph S. Shan
Sure. And certainly in the meantime, we feel the way its trending give us a high degree of confidence to advance our plans going forward going straight into Phase III.
Steven W. King
I think -- just to pop on that side, I think that is the key here is that we will be able to talk more about some of the statistics behind the results as we, again, the data matures somewhat. Especially, for the most meaningful endpoints, overall survival, progression-free survival. I think what has come through with this is I think there is a very nice trend toward the overall survival and the meaningfulness of that data. I think that's really what's driving the partnering interest, as well as our going into our internal planning on designing the Phase III study, which we do anticipate would have overall survival as primary endpoint. So I think that in addition, I think on the -- as far as the geography goes -- I mean a few things. As we've looked at the data, there is nothing standing out about any geography or subset of patients. They all seem to be favoring at this point the bavituximab treatment arms and that's held true throughout the study. So again, I think when we think about the results, it's really been clean across the board and really hasn't had any of those sort of issues where it throws a complexity in the Phase III trials. So very clean results. And again, we really look forward in the fall, where we've identified a couple of potential conferences to speak at and that will give us an opportunity to come out with a lot more color on the data.
Raluca Pancratov - Roth Capital Partners, LLC, Research Division
Very good. I'm glad to hear that. That's very, very helpful
A Svengali? I dont know, I only know he has CLEARLY stated:
1 Bavi is a placebo
2 Mngmt is deceiving, fixing trials
3 From 1 ... we conclude mgmt, Thorpe are big liars
Well, Bavi is certainly no placebo, at least for rats... and when I attended Dr. Thorpe's presentation in Barcelona he seemed to have a very broad recognition from his work... so I am convinced he is not deceiving anyone... So where does this leave D.D.?
Trying to make money from selling ATM shares may not be best choice for our own interest but maybe I would have taken the same approach if I were SK...
And I admit there might be some subtle issues coming from 2nd-line data, etc... but the bottom line is: "Is Bavi an alternate treatment for many diseases?"
Contrary to his opinion, It looks like it is, so I dont understand the sort of reverence some of you feel towards this character. I remember him when he was preaching about Transmeta (a semiconductor firm) and therefore a semiconductor Gurudevo at the time.
Of couse, all IMHO
Ha, ha , ha .... Good one Geo
Yeah!!! I still wonder how a prominent bio brain wastes his time reading a placebo-making biocompany board. I wouldn't.
Mind you I said "candidate"
Do you still think that is years away?
thx
Could Thorpe be a Nobel Prize candidate??
I am no expert but I wonder what the experts here may have to say.
That would certainly help PPS
FTM, I wouldnt worry about that
I guess my concern is that there would be uses
that would never get tried because one BP just would not have the resources to push research and
development across the whole range of possible uses.
FTC, great post. Bavi might be in a better situation than that
Any e.address or links where to send them?
just to save me time
thx
Thanks Dimitrios, I appreciate you bring this info to this board cause long ago I decided not to read YahooMB anymore
It is like High School kids debates
So, somebody is comitting a crime here...
According to DD... management is purposely lying, fixing the trial... and he seems to stick to "bavi is a placebo"
So either management should go to jail...
or it is maybe DD/AF the ones who should be investigated for lying or spreading FUD (fear, uncertainty & doubt) ... for the sake of some hidden agenda
time will tell... but the wrongdoer should have some price to pay
Whatever... But if Bavi really works who cares?
Trading with PPHM right now does not bother me... As news pop up so will the PPS
I am sure Mr. Placebo D.D. deserves this kind of message.
Making a statement such as "Bavi is a placebo" means there was no knowledge to back up his/her opinion
Yet, his/her agenda becomes very suspicious.
I am glad I did not pay attention to his comments
MM .. no point responding to the kid...
BTW, Didn't Damaj say he was the single shareholder owning more shares (non-options based)?
I like this: <<The Femprox cream was well tolerated with no serious adverse
events reported.
CONCLUSIONS
• In this large Phase 3 trial Femprox (topical alprostadil cream
0.4 % ) at a dose of 900 mcg showed statistically significant
improvements over placebo in all primary and secondary
endpoints with best efficacy observed in the age group < 45
years.
• The prevalence of local adverse events is similar in patients
< 45 years of age between all active treatment doses and
expected based on the pharmacodynamic effects of
alprostadil. More patients > 46 years of age reported mild to
moderate local adverse events with the 900 mcg dose.
• Results demonstrate the potential of Femprox® (topical
alprostadil cream 0.4 %) to become a safe and effective
pharmacotherapy for FSAD >>
thank MM
MM that was a wonderful insight, thx
FTM: It did not work for me either till I tried with IExplorer
Wow!!! I loved it.... Very promising.... everything
Yahoo board is a disaster... Not just only for APRI but for any other stock ... Good info gets mingled with all sortos of crazy posts.... Most of them deliberately crazy
Thanks for sharing this info with us. Very interesting
I like your optimism… but I see it feasible!
<<I retired from state government last year. Dealt with wastewater and later groundwater contamination. >>
Congrats… Here a structural engineer.
<<The question is, what events would have to happen to prevent us from getting to $20 by the end of 2013 (or much earlier)?
1. EMA problems with approving Vitaros...always a risk but it sure looks like approval is probable. >>
Canadian FDA seems to be pretty tough… so I am not concerned about that.
<<2. Problems with getting the room temp version approved... Also, I think Warner dropped the ball, stupidly. >>
Even more unlikely than # 1… And regarding Warner I am still puzzled he did not take the opportunity… and honestly… it bothers me a bit
<<3. A viable competitor surfaces...possible but any competitor will be years behind. >>
There is already one in the UK… but I take it as Chinese or Indian generic Viagra makers. They may not mean real harm
<<4. Challenges to Nexact patents...seems the company has spent some time and effort to protect itself here. >>
My believe is that Nexact is still to be fully exploited
<<5. Damaj gets ill or gets in an accident... >>
I agree with you… Damaj is da man
<<6. Vitaros sales are slow... >>
I dont think users will get into Vitaros composition and from my experience I know that urologists (at least mine) think Alprostadil is very efficient
<<7. Problems with getting other Nexact drugs approved (e.g., Femprox)...Vitaros can drive the price to $20 alone...hard to see that the company will hit a brick wall every place with Femprox or others. >>
Femprox can be a VERY pleasant surprise … but it may take longer than expected
Well Dimitrios that is a nice coincidence... we not only share our common interest in APRI, I am a Civil Engineer as well...
So if Vitaros alone can easily take PPS over $14, when considering FEMPROX and the rest of the pipeline... shall we reach $20 by the end of 2013?
Last week I had my prostate yearly check with my Doctor. (Boy, do I hate it!!!!)
Anyway I talked to the Urologist and mentioned him about Vitaros. He had not heard about it (I guess a bit too soon yet) but told me that Alprostadil was a better remedy to E.D. than pills (Viagra, etc.)
And I am sure that a cream (lotion) is better than a shot (THERE!)
He thought that if the effect of Vitaros were similar than the shot it would be a much better solution to ED than pills
Let's wait and see!!!
I also agree... But the only thing I didn't like was they said Vitaros will not be launched in France (rest of Europe) till 2013 2q ...
Just a potential patient complaint
MM Good info thx
Anatabloc and Parkinson's disease.... I have a close relative who suffers this illness. Does anyone know if Anatabloc could help ???
TIA
Now NJ's post makes more sense
Please do report back. I have a friend in the same situation
Paul V. Maier, CFO of Sequenom appointed to B.O.D. of APRI
Apricus Biosciences, Inc. (Nasdaq: APRI) announced that Paul V. Maier, Chief Financial Officer of Sequenom, Inc. (Nasdaq: SQNM) has been appointed to the Company's Board of Directors, effective June 1, 2012.
Is that good news?
To Present at the 2012 Jefferies Global Healthcare Conference
Apricus Biosciences' CEO to Present at the 2012 Jefferies Global Healthcare Conference
see the Company's web site at http://www.apricusbio.com
SAN DIEGO, May 29, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that Bassam Damaj, Ph.D., President and Chief Executive Officer, will present at the 2012 Jefferies Global Healthcare Conference, being held at The Grand Hyatt in New York City. Apricus Biosciences' presentation will take place on June 7, 2012 at 12:30pm Eastern Time.
Will he bring any news?
Nice!!!
Apricus Biosciences Strengthens Vitaros(R) and Nexact(R) Patent Estate With Two New Patent Allowances
http://finance.yahoo.com/news/apricus-biosciences-strengthens-vitaros-r-172130884.html
Wow!! Nice two articles ... thanks
I just wonder how much of this info goes to MD specialists....
Femprox seems to be a pretty good remedy
I thinks HH did a good presentation (replies)
Wish his eternal optimism ever becomes a reality
I enjoy your posts Dimitrios, thanks for posting...
However I dont quite agree with your last comments.
I dont know about you, but I am not Onassis nor Warren Buffet and I have always felt strange that APRI would have such an open relationship with individual investors like me... Talking on the phone, etc
Sure they need to communicate with shareholders as a whole but I dont expect them to reply to my enquiries... If they would do this with everybody it would be crazy... Either that or the size of the company is so small that is frightening...
IMHO
Isn't some FEMPROX news due within 2Q???
Apricus Biosciences Announces Poster Presentation of Femprox(R) Phase III Clinical Data at American Urological Association Annual Meeting
SAN DIEGO, May 4, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI - News) (http://www.apricusbio.com) announced today a poster titled, "Updated analyses of randomized, double-blind, Phase 3 study of Femprox(R), an alprostadil cream with a novel transdermal delivery technology for the treatment of female sexual arousal disorder (FSAD)," will be presented as a moderated poster (#1498) at the American Urological Association Annual Meeting which is being held May 19-23, 2012 in Atlanta, GA.
The poster presentation will discuss an updated analysis of the 400-women Phase III clinical trial conducted by the Company to provide further evidence of the statistically significant efficacy and safety profile of Apricus Bio's investigational drug, Femprox(R) (topical alprostadil 0.4 % cream), for the treatment of FSAD in pre- and post-menopausal women.
The data will be presented by Dr. Irwin Goldstein, Director of Sexual Medicine at the Alvarado Hospital in San Diego, and a member of Apricus Bio's Femprox(R) Clinical Advisory Board. Dr. Goldstein will present the data during the session titled: "Sexual Function/Dysfunction/Andrology: Medical and Non-Surgical Therapy," taking place Tuesday, May 22 from 8-10 a.m. local time. Dr. Goldstein will give a short oral presentation which will be followed by a question and answer period. Dr. Goldstein is the Editor of The Journal of Sexual Medicine, a member of numerous sexual medicine societies, the author or co-author of approximately 260 peer-reviewed papers, and an expert in the area of women's sexual health.
About Femprox(R)
http://finance.yahoo.com/news/apricus-biosciences-announces-poster-presentation-140500270.html
It is not official, but it seems the plant is running again
That is my understanding too
Well I understood it as samples... since there is no way that they can sell Vitaros in 2012
So, as mere samples, I dont see that figure as a revenue clue...
Dont you think?